The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What is MRD and why is it important in acute myeloid leukemia?
Jacqueline Cloos
September 21, 2021
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, Know AML spoke to Jacqueline Cloos, Amsterdam UMC, Amsterdam, NL. We asked, What is measurable residual disease (MRD) and why is it important in acute myeloid leukemia? Cloos begins by highlighting that the occurrence of relapse can lead to poor prognosis in acute myeloid leukemia and explains how MRD is one of the tools used to assess a patients risk of relapsing. MRD can be used to tailor treatment choices or monitor the disease during therapy, among other uses. Finally, Cloos outlines the standards around clinical implementation such as the European LeukemiaNet (ELN) MRD Working Party.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
